Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPG 7909 in renal cell carcinoma
NCT00043407Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2002
- Primary completion
- Sep 2004
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
01
Overview
Phase 2, open-label, single-arm trial of agatolimod in renal cell carcinoma (RCC), sponsored by Pfizer. Primary endpoints: Tolerability of escalating doses of subcutaneously administered CPG 7909 Injection, Maximum Tolerated Dose and 1 more. Started Mar 2002; status: completed.
02
Drugs
agatolimod
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00043407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00043407.